| Autor: |
G, Fonseca-González, M, Alamilla-Sánchez, V, García-Macas, J, Herrera-Acevedo, M, Villalobos-Brito, E, Tapia-Rangel, D, Maldonado-Tapia, M, López-Mendoza, J H, Cano-Cervantes, J, Orozco-Vázquez, D, Timarán-Montenegro, S, Cortés-Martínez, M, Escarela-Serrano, S, Muñoz-López, L, Montiel-López, P, Mondragón-Terán, J A, Suárez-Cuenca |
| Rok vydání: |
2022 |
| Zdroj: |
Scientific reports. 13(1) |
| ISSN: |
2045-2322 |
| Popis: |
The clinical course of COVID-19 may show severe presentation, potentially involving dynamic cytokine storms and T cell lymphopenia, which are leading causes of death in patients with SARS-CoV-2 infection. Plasma exchange therapy (PLEX) effectively removes pro-inflammatory factors, modulating and restoring innate and adaptive immune responses. This clinical trial aimed to evaluate the impact of PLEX on the survival of patients with severe SARS-CoV-2 and the effect on the cytokine release syndrome. Hospitalized patients diagnosed with SARS-CoV-2 infection and cytokine storm syndrome were selected to receive 2 sessions of PLEX or standard therapy. Primary outcome was all-cause 60-days mortality; secondary outcome was requirement of mechanical ventilation, SOFA, NEWs-2 scores modification, reduction of pro-inflammatory biomarkers and hospitalization time. Twenty patients received PLEX were compared against 40 patients receiving standard therapy. PLEX reduced 60-days mortality (50% vs 20%; OR 0.25, 95%CI 0.071-0.880; p = 0.029), and this effect was independent from demographic variables and drug therapies used. PLEX significantly decreased SOFA, NEWs-2, pro-inflammatory mediators and increased lymphocyte count, accompanied with a trend to reduce affected lung volume, without effect on SatO |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink